Key result
Higher GPR linked to ~74% greater ICU mortality after cardiac arrest.
Why the study?
Gamma-glutamyl transpeptidase to platelet ratio has been proposed as a new inflammatory marker, but its association with outcomes after cardiac arrest needed evaluation.
Does a higher gamma-glutamyl transpeptidase to platelet ratio (GPR) predict worse outcomes in patients after cardiac arrest?
Cohort (n=354)
No
Does a higher gamma-glutamyl transpeptidase to platelet ratio (GPR) predict worse outcomes in patients after cardiac arrest?
Odds Ratio: 1.738 (95% CI 1.221–2.474)
p-value: p=0.002
The gamma-glutamyl transpeptidase to platelet ratio (GPR) is a novel inflammatory marker that independently predicts ICU mortality, hospital mortality, and unfavorable neurologic outcomes in patients after cardiac arrest.
GPR may aid post-arrest risk stratification; extends inflammatory marker data but remains hypothesis-generating pending prospective validation.
Introduction . In recent years, gamma‐glutamyl transpeptidase to platelet ratio (GPR) has been proposed as a new inflammatory marker. We aimed to evaluate the association between GPR and outcomes after cardiac arrest (CA). Methods . A total of 354 consecutive patients with CA were included in this retrospective study. Patients were divided into three groups according to tertiles of GPR (low, n = 119; middle, n = 117; and high, n = 118). To determine the relationship between GPR and prognosis, a logistic regression analysis was performed. The ability of GPR to predict the outcomes was evaluated by receiver operating characteristic (ROC) curve analysis. Two prediction models were established, and the likelihood ratio test (LRT) and the Akaike Information Criterion (AIC) were utilized for model comparison. Results . Among the 354 patients (age 62 [52, 74], 254/354 male) who were finally included in the analysis, those in the high GPR group had poor outcomes. Multivariate logistic regression analysis revealed that GPR was independently associated with the three outcomes, for ICU mortality (odds ratios (OR) = 1.738, 95% confidence interval (CI): 1.221‐2.474, P = 0.002), hospital mortality (OR = 1.676[1.164 − 2.413], P = 0.005), and unfavorable neurologic outcomes (OR = 1.623[1.121 − 2.351], P = 0.010). The area under the ROC curve was 0.611 (95% Cl: 0.558‐0.662) for ICU mortality, 0.600 (95% CI: 0.547‐0.651) for hospital mortality, and 0.602 (95% CI: 0.549‐0.653) for unfavorable neurologic outcomes. Further, the LRT analysis showed that compared with the model without GPR, the GPR‐combined model had a higher likelihood ratio χ 2 score and smaller AIC. Conclusion . GPR, as an inflammatory indicator, was independently associated with outcomes after CA. GPR is helpful in estimating the clinical outcomes of patients with CA.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2021) conducted a cohort in Cardiac arrest (n=354). Gamma-glutamyl transpeptidase to platelet ratio (GPR) vs. Low GPR was evaluated on All-cause mortality during ICU stay (ICU mortality) (OR 1.738, 95% CI 1.221-2.474, p=0.002). Higher gamma-glutamyl transpeptidase to platelet ratio (GPR) was independently associated with increased ICU mortality (OR 1.738) in patients after cardiac arrest.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: